TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07605429: BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.

Sponsor: OHB Pediatrics Ltd. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 165 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$3,488,656

Rescue Site Savings

+$2,310,056

Unlock Full NCT07605429 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07605429 Rescue Dossier →